SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in a U.S. patent application for a combination therapy targeting binge behavior disorders [1][2] - The therapy combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines, such as Palmitoylethanolamide (PEA), which may provide a new approach to treating various behavioral addictions [2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs based on THC and non-psychoactive cannabidiol [4] - The company is currently working on treatments for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4] Collaboration Details - The collaboration with Clearmind focuses on the potential of PEA-MEAI combinations to address conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3] - Preclinical data suggests that this combination therapy may effectively mitigate binge episodes while preserving natural reward pathways [3] Clearmind Medicine Inc. Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing novel psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a diverse intellectual property portfolio consisting of 19 patent families and 31 granted patents [5]